Vistagen appoints Elissa Cote as Chief Corporate Development Officer

Vistagen Therapeutics, Inc.

Cote appointed CCDO effective June 23, 2025, to lead strategic partnerships and pherine platform advancement.
Nearly 30 years biopharma BD experience; previously Chief Strategy/BD Officer at Mallinckrodt Pharmaceuticals.
Received inducement option for 150,000 shares at June 23 closing price; vests 25% year one, then monthly over 36 months.
Pipeline includes five intranasal pherine candidates targeting six CNS disorders.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.